Tonix Pharmaceuticals
Tonix Pharmaceuticals is a NASDAQ-listed company developing therapeutics for central nervous system disorders, immunology conditions, infectious diseases, and rare diseases, with two FDA-approved products for acute migraine in adults.
Company Overview
Tonix Pharmaceuticals is a publicly traded biopharmaceutical company listed on the NASDAQ exchange under the ticker TNXP. The company focuses on developing therapeutics for central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. Tonix collaborates with government institutions, world-class academic and non-profit research organizations, and maintains license agreements with other biotech companies.
Research and Development
Tonix Pharmaceuticals has a robust pipeline of programs in development stages ranging from preclinical to preparing for NDA submission. The company's R&D efforts are supported by its Research and Development Center in Frederick, Maryland, which focuses on infectious diseases, and its Advanced Development Center in North Dartmouth, Massachusetts, which accelerates research, development, and analytical capabilities. Currently, Tonix is developing a variety of therapeutics across multiple therapeutic modalities, including small molecules and biologics.
Key Products and Therapies
Tonix markets two FDA-approved products for acute migraine in adults and is developing several key therapies. TNX-102 SL, the company's lead CNS candidate, is being developed for fibromyalgia, Long COVID, and acute stress disorder. TNX-1500, an anti-CD40L monoclonal antibody, targets organ transplant rejection and autoimmune conditions. TNX-1700 focuses on gastric and colorectal cancers. TNX-801 and TNX-1800 are live virus vaccines for smallpox, monkeypox, and COVID-19, respectively. TNX-2900, for Prader-Willi syndrome, has received Orphan Drug and Rare Pediatric Disease Designations from the FDA.
Collaborations and Partnerships
Tonix Pharmaceuticals collaborates with multiple esteemed entities, including government institutions, academic bodies, and non-profit research organizations. These collaborations enhance the company's capabilities and reach in its development pipeline. Tonix also has several license agreements with other biotech companies, further expanding its R&D efforts in multiple therapeutic areas.
Therapeutic Areas of Focus
Tonix Pharmaceuticals develops therapeutics for a range of conditions. In central nervous system disorders, the company is working on solutions for fibromyalgia, Long COVID, and acute stress disorder. In immunology, they are advancing TNX-1500 for organ transplant rejection and autoimmune conditions. The infectious disease portfolio includes TNX-801 and TNX-1800 vaccines. Tonix is also addressing rare diseases with TNX-2900 for Prader-Willi syndrome. Additional developments include TNX-1300 for cocaine intoxication and TNX-1900 for multiple conditions such as adolescent obesity and social anxiety disorder.